Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Jul 13, 2023 1:07pm
123 Views
Post# 35539657

RE:RE:RE:RE:RE:Speechless - Fire them all, really.

RE:RE:RE:RE:RE:Speechless - Fire them all, really.Those freebie warrants may prove to be a blessing in disguise for us as it does alter the incentives for Marathon in a meaningful way and aligns them more with common shareholders interests, assumeing the situation at THTX does not totally fall apart. I see no evidence at the moment that it is totally falling apart and note that Marathon undoubtedly extended the $20 million knowing THTX would fall below the $20 million level in the loan agreement and they have not told THTX to shut down the cancer research effort totally in order to focus 100% on repaying their loan. I suspect they have an eye on the upside of their warrants and know cancer could provide for that even though the loan was worked out only focusing on the legacy drug business.
PWIB123 wrote: I don't disagree with much of this, but Marathon got a freebie in terms of upside with warrants.  Let's not be fooled in that their number one priority is to get repaid first.  On the inventory front, they've already given warning that they'll likely have an issue with existing inventory that "might" expire.  It likely will.  I understood the customer issue, but they still ended up taking a hit in the end by way of adjusting revenue and apparently making it a part of their customer negotiation...assuming I read that correctly.  I've just never seen a company have so many setbacks in the midst of so many opportunities for upside.  History tends to repeat itself.


<< Previous
Bullboard Posts
Next >>